Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243719 · ClinicalTrials.gov registry record · Phase 1
Open-label Extension Study of ADP101
A Phase 1 study, sponsored by Alladapt Immunotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT05243719: Clinical Trial Phase 1 study, sponsored by Alladapt Immunotherapeutics.
NCT05243719 is a Phase 1 study that was terminated before completion, run by Alladapt Immunotherapeutics. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05243719, a Phase 1 study, was terminated before completion, sponsored by Alladapt Immunotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
Primary Outcome
Incidence of adverse events including serious adverse events during the study period.
Interventions
- BIOLOGICAL ADP101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 1 |
Why NCT05243719 stopped before completion
NCT05243719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 1 intervention - of which ADP101 is the first listed.
NCT05243719 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05243719 about?
NCT05243719 is a clinical study titled "Open-label Extension Study of ADP101". This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
What is the current status of trial NCT05243719?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-03-14. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05243719?
The interventions under investigation include: ADP101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05243719?
This trial is sponsored by Alladapt Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05243719's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI